The CD40-CD40L system in cardiovascular disease

Annals of Medicine

Volumn 43, Issue 5, 2011, Pages 331-340

  Pamukcu, Burak ^a   Lip, Gregory Y H ^a   Snezhitskiy, Viktor ^b   Shantsila, Eduard ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b GRODNO STATE MEDICAL UNIVERSITY   (Belarus)

Author keywords

Atherosclerosis; CD40; CD40L; coronary artery disease; infl ammation; sCD40L; thrombosis

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND;

ACUTE CORONARY SYNDROME; ANTIGEN PRESENTING CELL; ARTERY THROMBOSIS; ATHEROSCLEROSIS; AUTOCRINE EFFECT; B LYMPHOCYTE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; ENDOCRINE FUNCTION; HUMAN; INFLAMMATION; MAST CELL; NONHUMAN; PARACRINE SIGNALING; PATHOGENESIS; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

ANIMALS; ANTIGENS, CD40; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; CD40 LIGAND; FEMALE; HUMANS; INFLAMMATION; THROMBOSIS;

EID: 79959365729     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2010.546362     Document Type: Review

References (89)

1. Noelle RJ, Ledbetter JA, Aruffo A. CD40 and its ligand, an essential ligand-receptor pair for thymus-dependent B-cell activation. Immunol Today. 1992;13:431-3.
2. Ludewig B, Henn V, Schröder JM, Graf D, Kroczek RA. Induction, regulation, and function of soluble TRAP (CD40 ligand) during interaction of primary CD4+ CD45RA+ T cells with dendritic cells. Eur J Immunol. 1996;26:3137-43. (Pubitemid 26411524)
3. Van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol. 2000;67:2-17. (Pubitemid 30046812)
4. Kroczek RA, Graf D, Brugnoni D, Giliani S, Korthauer U, Ugazio A, et al. Defective expression of CD40 ligand on T cells causes X-linked immunodefi ciency with hyper-IgM (HIGM1). Immunol Rev. 1994;138:39-59. (Pubitemid 24147415)
5. Gauchat JF, Henchoz S, Mazzei G, Aubry JP, Brunner T, Blasey H, et al. Induction of human IgE synthesis in B cells by mast cells and basophils. Nature. 1993;365:340-3. (Pubitemid 23288974)
6. Gauchat JF, Henchoz S, Fattah D, Mazzei G, Aubry JP, Jomotte T, et al. CD40 ligand is functionally expressed on human eosinophils. Eur J Immunol. 1995;25:863-5.
7. Hermann A, Rauch BH, Braun M, Schror K, Weber AA. Platelet CD40 ligand-subcellullar localization, regulation of expression, and inhibition by clopidogrel. Platelets. 2001;12: 74-82. (Pubitemid 32281113)
8. Armitage RJ, Fanslow WC, Strockbine L, Sato TA, Clifford KN, Macduff BM, et al. Molecular and biological characterization of a murine ligand for CD40. Nature. 1992;357:80-2.
9. Graf D, Korthauer GD, Mages HW, Senger G, Kroczek RA. Cloning of TRAP, a ligand for CD40 on human T cells. Eur J Immunol. 1992;22:3191-4.
10. Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci. 2001;58:4-43. (Pubitemid 32143961)
11. Chen Y, Chen J, Xiong Y, Da Q, Xu Y, Jiang X, et al. Internalization of CD40 regulates its signal transduction in vascular endothelial cells. Biochem Biophys Res Commun. 2006;345:106-17.
12. Schonbeck U, Libby P. CD40 signaling and plaque instability. Circ Res. 2001;89:1092-103. (Pubitemid 34627866)
13. Zirlik A, Bavendiek U, Libby P, MacFarlane L, Gerdes N, Jagielska J, et al. TRAF-1, -2, -3, -5, and -6 are induced in atherosclerotic plaques and differentially mediate proinfl ammatory functions of CD40L in endothelial cells. Arterioscler Thromb Vasc Biol. 2007;27:1101-7. (Pubitemid 46641965)
14. Urbich C, Mallat Z, Tedgui A, Clauss M, Zeiher AM, Dimmeler S. Upregulation of TRAF-3 by shear stress blocks CD40-mediated endothelial activation. J Clin Invest. 2001; 108:1451-8. (Pubitemid 33091982)
15. Arron JR, Pewzner-Jung Y, Walsh MC, Kobayashi T, Choi Y. Regulation of the subcellular localization of tumor necrosis factor receptor associated factor (TRAF)2 by TRAF1 reveals mechanisms of TRAF2 signaling. J Exp Med. 2002;196: 923-34.
16. Missiou A, Wolf D, Platzer I, Ernst S, Walter C, Rudolf P, et al. CD40L induces infl ammation and adipogenesis in adipose cells - a potential link between metabolic and cardiovascular disease. Thromb Haemost. 2010;103:788-96.
17. Donners MM, Beckers L, Lievens D, Munnix I, Heemskerk J, Janssen BJ, et al. The CD40-TRAF6 axis is the key regulator of the CD40/CD40L system in neointima formation and arterial remodeling. Blood. 2008;111:4596-604.
18. Zapata JM. TNF-receptor-associated factors as targets for drug development. Expert Opin Ther Targets. 2003;7:411-25. (Pubitemid 36722226)
19. Lutgens E, Lievens D, Beckers L, Wijnands E, Soehnlein O, Zernecke A, et al. Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J Exp Med. 2010;207:391-404.
20. Wenzel F, Baertl A, Zimmermann N, Hohlfeld T, Giers G, Oldenburg J, et al. Different behaviour of soluble CD40L concentrations can be reflected by variations of preanalytical conditions. Clin Hemorheol Microcirc. 2008;39:417-22. (Pubitemid 352040027)
21. Henn V, Steinbach S, Büchner K, Presek P, Kroczek RA. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood. 2001;98:1047-54.
22. Reinboldt S, Wenzel F, Rauch BH, Hohlfeld T, Grandoch M, Fischer JW, et al. Preliminary evidence for a matrix metalloproteinase- 2 (MMP-2)-dependent shedding of soluble CD40 ligand (sCD40L) from activated platelets. Platelets. 2009;20: 441-4.
23. Inwald DP, McDowall A, Peters MJ, Callard RE, Klein NJ. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res. 2003;92: 1041-8. (Pubitemid 36588504)
24. Matthies KM, Newman JL, Hodzic A, Wingett DG. Differential regulation of soluble and membrane CD40L proteins in T cells. Cell Immunol. 2006;241:47-58. (Pubitemid 44444899)
25. Hsu YM, Lucci J, Su L, Ehrenfels B, Garber E, Thomas D. Heteromultimeric complexes of CD40 ligand are present on the cell surface of human T lymphocytes. J Biol Chem. 1997; 272:911-5. (Pubitemid 27035013)
26. H irohata S. Human Th1 responses driven by IL-12 are associated with enhanced expression of CD40 ligand. Clin Exp Immunol. 1999;115:78-85. (Pubitemid 29030366)
27. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391:591-4. (Pubitemid 28157601)
28. Foy TM, Aruffo A, Bajorath J, Buhlmann JE, Noelle RJ. Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol. 1996;14:591-617. (Pubitemid 26130658)
29. Chakrabarti S, Varghese S, Vitseva O, Tanriverdi K, Freedman JE. CD40 ligand influences platelet release of reactive oxygen intermediates. Arterioscler Thromb Vasc Biol. 2005;25:2428-34. (Pubitemid 41552666)
30. Prasad KS, Andre P, He M, Bao M, Manganello J, Phillips DR. Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling. Proc Natl Acad Sci USA. 2003;100:12367-71. (Pubitemid 37271566)
31. Crow AR, Leytin V, Starkey AF, Rand ML, Lazarus AH. CD154 (CD40 ligand)-Deficient mice exhibit prolonged bleeding time and decreased shear-induced platelet aggregates. J Thromb Haemost. 2003;1:850-2.
32. Cipollone F, Mezzetti A, Porreca E, Di Febbo C, Nutini M, Fazia M, et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia. Effects of statin therapy. Circulation. 2002;106:399-402. (Pubitemid 34803680)
33. Enomoto Y, Adachi S, Matsushima-Nishiwaki R, Doi T, Niwa M, Akamatsu S, et al. Thromboxane A(2) promotes soluble CD40 ligand release from human platelets. Atherosclerosis. 2010;209:415-21.
34. Lievens D, Zernecke A, Seijkens T, Soehnlein O, Beckers L, Munnix IC, et al. Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood. 2010;116: 4317-27.
35. Aukrust P, Damas JK, Solum NO. Soluble CD40 ligand and platelets: self-perpetuating pathogenic loop in thrombosis and inflammation? J Am Coll Cardiol. 2004;43:2326-8. (Pubitemid 38757606)
36. Nannizzi-Alaimo L, Alves VL, Phillips DR. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation. 2003;107:1123-8. (Pubitemid 36297203)
37. Furman MI, Krueger LA, Linden MD, Barnard MR, Frelinger III AL, Michelson AD. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Coll Cardiol. 2004;43:2319-25. (Pubitemid 38757605)
38. Garlichs CD, Eskafi S, Raaz D, Schmidt A, Ludwig J, Herrmann M, et al. Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. Heart. 2001;86:649-55. (Pubitemid 33086881)
39. Aggarwal A, Schneider DJ, Terrien EF, Sobel, BE, Dauerman HL. Increased coronary arterial release of interleukin- 1 receptor antagonist and soluble CD40 ligand indicative of inflammation associated with culprit coronary plaques. Am J Cardiol. 2004;93:6-9. (Pubitemid 38022025)
40. Zirlik A, Maier C, Gerdes N, MacFarlane L, Soosairajah J, Bavendiek U, et al. CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1. Circulation. 2007;115:1571-80. (Pubitemid 46648642)
41. Penno G, Pucci L, Dell'O mo G, Lucchesi D, Miccoli R, Del Prato S, et al. Soluble CD40 ligand levels in essential hypertensive men: evidence of a possible role of insulin resistance. Am J Hypertens. 2009;22:1007-13.
42. Lim HS, Blann AD, Lip GYH. Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus. Relationships to cardiovascular disease and risk factor intervention. Circulation. 2004;109:2524-8. (Pubitemid 38720551)
43. Harding SA, Sarma J, Josephs DH, Cruden NL, Din JN, Twomey PJ, et al. Upregulation of the CD40/CD40 ligand dyad and platelet-monocyte aggregation in cigarette smokers. Circulation. 2004;109:1926-9. (Pubitemid 38544479)
44. Schonbeck U, Gerdes N, Varo N, Reynolds RS, Horton DB, Bavendiek U, et al. Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation. 2002;106:2888-93. (Pubitemid 35424737)
45. Andre P, Prasad KS, Denis CV, He M, Papalia JM, Hynes RO, et al. CD40L stabilizes arterial thrombi by a B3 integrindependent mechanism. Nat Med. 2002;8:247-52. (Pubitemid 34250102)
46. R obertson AK, Hansson GK. T cells in atherogenesis: for better or for worse? Arterioscler Thromb Vasc Biol. 2006;26: 2421-32. (Pubitemid 44607461)
47. Wagner AH, Guldenzoph B, Lienenluke B Hecker M. CD154/CD40-mediated expression of CD154 in endothelial cells: consequences for endothelial cell-monocyte interaction. Arterioscler Thromb Vasc Biol. 2004;24:715-20. (Pubitemid 38451609)
48. Smook ML, Heeringa P, Damoiseaux JG, Daemen MJ, de Winther MP, Gijbels MJ, et al. Leukocyte CD40L defi - ciency affects the CD25(+ ) CD4 T cell population but does not affect atherosclerosis. Atherosclerosis. 2005;183: 275-82. (Pubitemid 41579278)
49. Hristov M, Gümbel D, Lutgens E, Zernecke A, Weber C. Soluble CD40 ligand impairs the function of peripheral blood angiogenic outgrowth cells and increases neointimal formation after arterial injury. Circulation. 2010;121: 315-24.
50. Varo N, de Lemos JA, Libby P, Morrow DA, Murphy SA, Nuzzo R, et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation. 2003;108:1049-52. (Pubitemid 37071512)
51. Cipollone F, Ferri C, Desideri G, Paloscia L, Materazzo G, Mascellanti M, et al. Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty. Circulation. 2003;108: 2776-82. (Pubitemid 37498980)
52. Mach F, Schonbeck U, Bonnefoy JY, Pober JS, Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation. 1997;96:396-9. (Pubitemid 27329409)
53. Bavendiek U, Libby P, Kilbride M, Reynolds R, Mackman N, Schonbeck U. Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1. J Biol Chem. 2002;277:25032-9. (Pubitemid 34951807)
54. Blann AD, Tan KT, Tayebjee MH, Davagnanam I, Moss M, Lip GY. Soluble CD40L in peripheral artery disease. Relationship with disease severity, platelet markers and the effects of angioplasty. Thromb Haemost. 2005;93:578-83. (Pubitemid 40392550)
55. Pamuk GE, Vural O, Turgut B, Demir M, Pamuk ON, Cakir N. Increased platelet activation markers in rheumatoid arthritis: are they related with subclinical atherosclerosis? Platelets. 2008;19:146-54. (Pubitemid 351302382)
56. Aukrust P, Muller F, Ueland T, Berget T, Aaser E, Brunsvig A, et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation. 1999;100:614-20. (Pubitemid 29379750)
57. Schonbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD40L and cardiovascular risk in women. Circulation. 2001;104:2266-8. (Pubitemid 33049505)
58. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003;348:1104-11. (Pubitemid 36337321)
59. Davi G, Tuttolomondo A, Santilli F, Basili S, Ferrante E, Di Raimondo D, et al. CD40 ligand and MCP-1 as predictors of cardiovascular events in diabetic patients with stroke. J Atheroscler Thromb. 2009;16:707-13.
60. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Sasiela WJ, Szarek M, et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation. 2004;110:386-91. (Pubitemid 38993846)
61. Verma S, Wang CH, Li SH, Lonnb E, Charbonneau F, Title LM, et al. The relationship between soluble CD40 ligand levels and Framingham coronary heart disease risk score in healthy volunteers. Atherosclerosis. 2005;182:361-5. (Pubitemid 41267205)
62. Morrow DA, Sabatine MS, Brennan ML, de Lemos JA, Murphy SA, Ruff CT, et al. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J. 2008;29:1096-102. (Pubitemid 351844877)
63. Blann AD, Choudhury A, Freestone B, Patel J, Lip GY. Soluble CD40 ligand and atrial fi brillation: relationship to platelet activation, and endothelial damage/dysfunction. Int J Cardiol. 2008;127:135-7. (Pubitemid 351707516)
64. Ferro D, Loffredo L, Polimeni L, Fimognari F, Villari P, Pignatelli P, et al. Soluble CD40 ligand predicts ischemic stroke and myocardial infarction in patients with nonvalvular atrial fi brillation. Arterioscler Thromb Vasc Biol. 2007;27: 2763-8. (Pubitemid 350158934)
65. Choudhury A, Chung I, Panja N, Patel J, Lip GYH. Soluble CD40 ligand, platelet surface CD40 ligand, and total platelet CD40 ligand in atrial fi brillation. Relationship to soluble p-selectin, stroke risk factors, and risk factor intervention. Chest. 2008;134:574-81.
66. Antoniades C, Van-Assche T, Shirodaria C, Diesch J, Antonopoulos AS, Lee J, et al. Preoperative sCD40L levels predict risk of atrial fi brillation after off-pump coronary artery bypass graft surgery. Circulation. 2009;120: S170-S6.
67. Chung I, Choudhury A, Patel J, Lip GY. Soluble CD40L, platelet surface CD40L and total platelet CD40L in congestive heart failure: relationship to platelet volume, mass and granularity. J Intern Med. 2008;263:313-21. (Pubitemid 351207347)
68. Langer F, Ingersoll SB, Amirkhosravi A, Meyer T, Siddiqui FA, Ahmad S, et al. The role of CD40 in CD40L- and antibodymediated platelet activation. Thromb Haemost. 2005;93: 1137-46. (Pubitemid 40823520)
69. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med. 2000; 6:114. (Pubitemid 30082329)
70. Mach F, Schön beck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature. 1998;394:200-3. (Pubitemid 28325976)
71. Lutgens E, Gorelik L, Daemen MJ, de Muinck ED, Grewal IS, Koteliansky VE, et al. Requirement for CD154 in the progression of atherosclerosis. Nat Med. 1999;5:1313-6. (Pubitemid 29535611)
72. Sch ön beck U, Sukhova G, Shimizu K, Mach F, Libby P. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci USA. 2000; 7458:458-63.
73. Lutgens E, Cleutjens KB, Heeneman S, Koteliansky VE, Burkly LC, Daemen MJ. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Natl Acad Sci USA. 2000;97:7464-9. (Pubitemid 30431486)
74. Ahn ER, Lander G, Jy W, Bidot CJ, Jimenez JJ, Horstman LL, et al. Differences of soluble CD40L in sera and plasma: Implications on CD40L assay as a marker of thrombotic risk. Thromb Res. 2004;114:143-8. (Pubitemid 39078587)
75. Mason PJ, Chakrabarti S, Albers AA, Rex S, Vitseva O, Varghese S, et al. Plasma, serum and platelet expression of CD40 ligand in adults with cardiovascular disease. Am J Cardiol. 2005;96:1365-9. (Pubitemid 41566614)
76. Weber M, Rabenau B, Stanisch M, Nef HM, M öl lmann H, Els ässer A, et al. Influence of sample type on soluble CD40 ligand assessment in patients with acute coronary syndromes. Thromb Res. 2007;120:811-4. (Pubitemid 47418234)
77. Riondino S, Martini F, La Farina F, Spila A, Guadagni F, Ferroni P. Increased plasma levels of soluble CD40 ligand correlate with platelet activation markers and underline the need for standardized pre-analytical conditions. Clin Biochem. 2010;43:666-70.
78. Ivandic BT, Spanuth E, Haase D, Lestin HG, Katus HA. Increased plasma concentrations of soluble cd40 ligand in acute coronary syndrome depend on in vitro platelet activation. Clin Chem. 2007;53:1231-4. (Pubitemid 47020978)
79. Varo N, Nuzzo R, Natal C, Libby P, Schonbeck U. Influence of pre-analytical and analytical factors on soluble CD40L measurements. Clin Sci (Lond). 2006;111:341-7. (Pubitemid 44690192)
80. Wykrzykowska JJ, Warnholtz A, de Jaeger P, Curzen N, Oldroyd KG, Collet JP, et al. Effect of clopidogrel discontinuation at 1 year after drug eluting stent placement on soluble CD40L, P-selectin and C-reactive protein levels: DECADES (Discontinuation Effect of Clopidogrel After Drug Eluting Stent): a multicenter, open-label study. J Thromb Thrombolysis. 2009;28:410-7.
81. Olenchock BA, Wiviott SD, Murphy SA, Cannon CP, Rifai N, Braunwald E, et al. Lack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16. J Thromb Thrombolysis. 2008;26:79-84.
82. Novo S, Basili S, Tantillo R, Falco A, Davì V, Novo G, et al. Soluble CD40L and cardiovascular risk in asymptomatic low-grade carotid stenosis. Stroke. 2005;36:673-5. (Pubitemid 40344177)
83. Malarstig A, Lindahl B, Wallentin L, Siegbahn A. Soluble CD40L levels are regulated by the -3459 A+ G polymorphism and predict myocardial infarction and the efficacy of antithrombotic treatment in non-ST elevation acute coronary syndrome. Arterioscler Thromb Vasc Biol. 2006;26:1667-73. (Pubitemid 44288999)
84. Manenti ER, Bodanese LC, Camey SA, Polanczyk CA. Prognostic value of serum biomarkers in association with TIMI risk score for acute coronary syndromes. Clin Cardiol. 2006;29:405-10. (Pubitemid 44353328)
85. Apple FS, Pearce LA, Chung A, Ler R, Murakami MM. Multiple biomarker use for detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome. Clin Chem. 2007;53:874-81. (Pubitemid 46744243)
86. Obradovic SD, Antovic JP, Antonijevic NM, Ratkovic NG, Vojvodic DV, Subota VS, et al. Elevations in soluble CD40 ligand in patients with high platelet aggregability undergoing percutaneous coronary intervention. Blood Coagul Fibrinolysis. 2009;20:283-9.
87. Rondina MT, Lappé JM, Carlquist JF, Muhlestein JB, Kolek MJ, Horne BD, et al. Soluble CD40 ligand as a predictor of coronary artery disease and long-term clinical outcomes in stable patients undergoing coronary angiography. Cardiology. 2008;109:196-201. (Pubitemid 351220522)
88. Tousoulis D, Antoniades C, Nikolopoulou A, Koniari K, Vasiliadou C, Marinou K, et al. Interaction between cytokines and sCD40L in patients with stable and unstable coronary syndromes. Eur J Clin Invest. 2007;37:623-8. (Pubitemid 47063099)
89. Tanne D, Haim M, Goldbourt U, Boyko V, Reshef T, Adler Y, et al. CD40 ligand and risk of ischemic stroke or coronary events in patients with chronic coronary heart disease. Int J Cardiol. 2006;107:322-6. (Pubitemid 43287775)